Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
UBS
Healthtrust
Farmers Insurance
Daiichi Sankyo
Moodys
Federal Trade Commission
AstraZeneca
QuintilesIMS

Generated: October 19, 2017

DrugPatentWatch Database Preview

Apraclonidine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for apraclonidine hydrochloride and what is the scope of apraclonidine hydrochloride freedom to operate?

Apraclonidine hydrochloride
is the generic ingredient in two branded drugs marketed by Novartis Pharms Corp and Akorn Inc, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for apraclonidine hydrochloride. Three suppliers are listed for this compound.

Summary for Generic Name: apraclonidine hydrochloride

US Patents:0
Tradenames:2
Applicants:2
NDAs:3
Drug Master File Entries: see list3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list37
Clinical Trials: see list2,284
Patent Applications: see list267
Therapeutic Class:Ophthalmic Agents
Drug Prices:see low prices
DailyMed Link:apraclonidine hydrochloride at DailyMed

Pharmacology for Ingredient: apraclonidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
IOPIDINE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC019779-001Dec 31, 1987RXYesYes► Subscribe► Subscribe► Subscribe
Akorn Inc
APRACLONIDINE HYDROCHLORIDE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC077764-001Mar 12, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
IOPIDINE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020258-001Jul 30, 1993ATRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: apraclonidine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
IOPIDINE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020258-001Jul 30, 1993► Subscribe► Subscribe
Novartis Pharms Corp
IOPIDINE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC019779-001Dec 31, 1987► Subscribe► Subscribe
Novartis Pharms Corp
IOPIDINE
apraclonidine hydrochloride
SOLUTION/DROPS;OPHTHALMIC019779-001Dec 31, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Fuji
Healthtrust
US Army
McKinsey
McKesson
Medtronic
Novartis
Farmers Insurance
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot